Regulatory and Compliance Updates news (page 8)

• 

  15 May 2026

  EnviTec Biogas: solid 2025; regulatory setbacks dent 2026, growth expected from 2027

  Total output +6.8% to €376.4M; revenues -7.4% to €312.6M; EBT €26.0M (prev €44.0M) after ~€8M provision; dividend suspended. 2026 guidance: revenues €330–370M, EBT €5–15M.
• 

  14 May 2026

  PureCycle: NJDEP Qualifies PureFive® Resin as Recycled Content

  NJDEP grants one-year conditional PCR designation under NJ recycled-content law; firm will seek permanent approval. Resin cleared for food-contact rigid packaging; 10.5M lb NJ feedstock sourced 2025
• 

  14 May 2026

  Iberdrola begins commissioning Tâmega wind‑hydro complex

  Tâmega Norte enters commissioning as the Iberian Peninsula's first grid-connected wind‑hydro hybrid: 195 MW (27×7.2 MW), ~414 GWh/yr; €346M for both farms; >230,000 t CO2/yr avoided.
• 

  14 May 2026

  Chugai, Nippon Shinyaku file Gazyva (obinutuzumab) for idiopathic nephrotic syndrome

  Phase III INShore showed improved sustained remission and steroid reduction versus MMF; no new safety signals, supporting a regulatory application.
• 

  14 May 2026

  Johnson Matthey 2026 PGM Market Report

  PGM prices surged; platinum hit record. 2026: deficits likely for platinum, ruthenium, iridium; palladium and rhodium may have small surpluses. Strong prices boost recycling; industrial demand firm.
• 

  14 May 2026

  Sinopec confirms 2,356.87 bcm proven reserves at Ziyang Dongfeng ultra-deep shale gas field

  Cambrian Qiongzhusi shale at 4,500–5,200 m poses high-temp, high-pressure, hard-to-drill reservoir challenges. Team developed new geological model, AI imaging and ultra‑deep drilling/fracturing tech.

• 

  12 May 2026

  Messer Belgium builds sustainable air separation plant at North Sea Port

  €60M investment creates 30 jobs to produce oxygen, nitrogen and argon; construction starts mid‑May, commissioning by 2028, CO2‑free operation using green electricity; serves Lille‑Rotterdam axis
• 

  12 May 2026

  ABO Energy achieves restructuring milestones and defines strategic priorities

  Restructuring draft finds firm viable; sets strategic action areas. Targets sustainable financing by end-July. Won 7.8 MW solar tariff, bid >150 MW wind, sold 16.8 MW farm and 4.5 MW turbine.
• 

  12 May 2026

  Eni and MSC Cruises test Enilive HVO diesel on cruise ship

  Pure HVO ran ~2,000 hours on a ship engine with no modifications; matched fuel performance, cut NOx ~16% and particulates, and cut lifecycle GHG ~80%. Validated by maker and independent certifier.
• 

  11 May 2026

  Petrobras posts R$32.7 billion net profit in 1Q26

  Net profit R$32.7bn; adjusted EBITDA R$59.6bn; investments R$26.8bn. Production and refining records supported cash generation and higher derivatives output.
• 

  11 May 2026

  LanzaTech selects North Sea Port, Ghent for Europe’s first commercial ATJ SAF plant

  €500M ATJ project targeting 79,000 t/yr SAF and 9,000 t/yr renewable diesel; EIA scoping filed; ~50 permanent jobs and ~300 FTE construction; FEED complete; EU Horizon support.
• 

  11 May 2026

  Ørsted and PGE start Baltica 2 offshore installation

  First foundations installed for a 1.5 GW offshore wind farm. 111 monopiles (107 turbine, 4 substation) to be installed through Q4 2026; commissioning expected in 2027; 25-yr CfD.
• 

  11 May 2026

  GSK partners with Sino Biopharmaceutical (CTTQ) for exclusive China launch of bepirovirsen

  Potential first-in-class CHB treatment under priority review in China; deal provides access to 5,000+ medical centres at launch, local import/distribution, hospital access and initial 5.5-yr supply.
• 

  9 May 2026

  Uniper demolishes Scholven towers D & E for H2-ready CCGT

  Two 114 m cooling towers were demolished at 11:00; ~15,000 t of concrete will be recycled for site backfill. Demolition used a coordinated safety plan; no resident evacuations.
• 

  8 May 2026

  argenx: FDA expands VYVGART/VYVGART Hytrulo approval to all adult gMG patients

  Phase-3 ADAPT SERON: VYVGART showed rapid, significant, sustained improvements across anti-MuSK, anti-LRP4 and triple-seronegative gMG; safety consistent; IV/SC options; access support.
• 

  8 May 2026

  Clariant Q1 2026: Resilient performance amid Middle East conflict

  Q1 sales down 2% (CHF918m); EBITDA margin fell to 17.5% (-130bp). Free cash-flow conversion rose to 54%. CHF80m savings program on track; 2026 guidance unchanged amid conflict
• 

  8 May 2026

  MOL Group Q1 2026: USD 212m profit amid supply disruptions and price controls

  Higher hydrocarbon prices lifted upstream; production 95.5 mboepd. Downstream hit by lower refining volumes and feedstock scarcity; Rijeka delayed coker opened. Consumer services and circulars rose.
• 

  7 May 2026

  argenx Q1 2026 Financial Results & Business Update

  Q1 product sales $1.3B (+63% YoY); profit $366M; PDUFA May 10 for seronegative gMG; VYVGART label expansions, multiple pipeline readouts in 2026–27; cash $4.9B
• 

  7 May 2026

  EU, Brazil and China launch Open Coalition on Compliance Carbon Markets

  New coalition to strengthen domestic carbon markets: improve MRV, accounting, transparency and offsets. Open to nations with national compliance schemes; New Zealand and Germany have joined.
• 

  7 May 2026

  PureCycle Achieves A3 CosPaTox Rating for Leave‑On Cosmetic‑Grade PureFive Resin

  Independent study shows dissolution recycling converts post‑consumer polypropylene into A3 leave‑on cosmetic grade resin commercially, removing contaminants, retaining performance and lowering CO₂
• 

  7 May 2026

  Moeve Q1 2026 Clean CCS EBITDA €506m, ramps Spain energy-transition capex

  Q1 net income €147m; capex €272m (69% to energy transition); operating cash flow €283m; FID for 300MW Andalusian green hydrogen; non-binding talks with Galp; net debt €2.56bn (1.6x).
• 

  7 May 2026

  Indaver pauses processing of highly PFAS-contaminated waste

  Authorities demand extra measurements and monitoring after limited historical soil contamination; four PFAS streams will be suspended while datasets and remediation checks are expanded.
• 

  7 May 2026

  UPM, Michelman and BOBST launch EU‑compliant bio‑based paper packaging concepts

  Two paper packaging concepts for EU SUPD: fiber papers with bio-based coatings giving moisture/mineral-oil and oxygen barriers, wide heat-seal window, recyclable/compostable, production-ready.
• 

  6 May 2026

  PureCycle Technologies Q1 2026 Results

  Ironton turnaround finished early/under budget; record 8.4M lb production (~10M lb feedstock); 5th consecutive revenue growth; two P&G approvals; Q1 net loss $33.4M; liquidity $131M.
• 

  5 May 2026

  Merck acquires Terns Pharmaceuticals

  Adds TERN‑701, an oral allosteric BCR::ABL1 TKI with FDA Breakthrough for certain CML patients. Bought via $53/share tender and merger; ~$5.8B R&D charge; Terns now delisted and private.
• 

  5 May 2026

  LANXESS Lewatit MDS TP 108 Removes >99.9% PFAS at Chemours

  Selective monodisperse ion-exchange resin removed >99.9% of fluorinated organics in wastewater, targeting short-chain PFAS via a 3-stage RO, carbon, resin cascade; spent resin incinerated.
• 

  4 May 2026

  BASF Engineering Plastics Certified to EN 45545 Railway Standard

  Ultramid and Ultradur grades certified to EN 45545 for railway E&E. Halogen‑free flame retardants (intumescent, Mg(OH)2), color‑independent approval and defined thicknesses for design freedom.
• 

  4 May 2026

  UPM and BASF advance recyclable fiber-based packaging

  Barrier papers paired with Joncryl HPB coatings enable high-performance, recyclable fiber-based packaging; samples to be shown at interpack 2026, supporting design-for-recycling rules.
• 

  2 May 2026

  thyssenkrupp AG, Jindal pause talks on thyssenkrupp Steel stake

  Steel unit's outlook improves after restructuring and IG Metall agreement; EU trade protections and CBAM increase stability. Goal: autonomous, profitable steel business; parent may keep minority stake
• 

  1 May 2026

  Novo Nordisk launches Ozempic pill — FDA‑approved oral semaglutide for adults with type 2 diabetes

  Tablets (1.5, 4, 9 mg) debut in US May 4. Reformulated from Rybelsus, available at 70,000+ pharmacies; insurance from $25; self-pay $149/199/299/month. Approved to reduce cardiovascular events